Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024706 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
A Phase 2 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT07024706 is a Phase 2 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 80 participants.
The verdict
NCT07024706, a Phase 2 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
Interventions
- DRUG Venetoclax
- DRUG Acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-06-04 |
| Est. Completion | 2033-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07024706
The ClinicalTrials.gov registry entry for NCT07024706 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venetoclax is the first listed.
NCT07024706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07024706 about?
NCT07024706 is a clinical study titled "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab". This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
What is the current status of trial NCT07024706?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-06-04. Estimated completion is 2033-03-23.
What interventions are being tested in trial NCT07024706?
The interventions under investigation include: Venetoclax (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT07024706?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.